Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477528 · ClinicalTrials.gov registry record
Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 201
- Enrollment target
NCT01477528: Completed study, sponsored by Abbott Medical Devices.
NCT01477528 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01477528 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 201 participants
- Enrollment target
Study Summary
The purpose of this observational study is to obtain multi-center data on HeartMate II (HMII) patients managed with reduced anticoagulation or anti-platelet regimes, and the incidence of thrombotic and bleeding adverse events associated with these regimes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-08 |
What the finished NCT01477528 record still lists
NCT01477528 is an observational study that tracks outcomes without assigning an intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01477528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01477528 about?
NCT01477528 is a clinical study titled "Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)". The purpose of this observational study is to obtain multi-center data on HeartMate II (HMII) patients managed with reduced anticoagulation or anti-platelet regimes, and the incidence of thrombotic and bleeding adverse events associated with these regimes.
What is the current status of trial NCT01477528?
This trial is currently completed. The enrollment target is 201 participants. The study started on 2011-11. Estimated completion is 2015-08.
Who is sponsoring clinical trial NCT01477528?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia